Clinical Trials Directory

Phase 2 Trial Oral Enzastaurin in Prostate Cancer Patients Who Have Rising PSA (1) During Hormonal Manipulation and (2) After First-Line Cytotoxic Chemotherapy

The purpose is to see how quickly two different types of prostate cancer patients respond when taking enzastaurin. Cohort 1 - asymptomatic patients with androgen-independent PSA-progressive disease with or without clinical or radiographic evidence of metastatic disease. Cohort 2 - patients with androgen-independent metastatic prostate cancer (documented bone or soft tissue metastases) with rising PSA, clinical, radiographic disease progression following one prior docetaxel-based regimen

Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.

Investigator(s):

Intervention(s):

  • drug : Enzastaurin

Phase: Phase 2

Eligibility

Ages Eligible For Study:

18 Years - N/A

Inclusion Criteria

- You are expected to be alive in the 12 weeks. - You are at least 18 years old. - You live close enough to the doctor's office to attend all of your required visits. - You have not been treated with chemotherapy for your prostate cancer (cohort 1). - You have had one prior docetaxel-based chemotherapy regimen (cohort 2). - You have evidence of metastatic prostate cancer with bone or soft tissue disease (cohort 2). - Your organs must be functioning properly.

External Links

Explore related trials

Contact information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Denise Haas
6507361252
Not Recruiting

Footer Links: